Compare · CERS vs CTSH
CERS vs CTSH
Side-by-side comparison of Cerus Corporation (CERS) and Cognizant Technology Solutions Corporation (CTSH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and CTSH operate in EDP Services (Technology), so they compete in similar markets.
- CTSH is the larger of the two at $29.63B, about 65.0x CERS ($455.4M).
- CTSH has been more active in the news (11 items in the past 4 weeks vs 1 for CERS).
- CTSH has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- Cognizant Technology Solutions Corporation
- Price
- -
- -
- Market cap
- $455.4M
- $29.63B
- 1M return
- -
- +6.71%
- 1Y return
- -
- -1.00%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 1998
- News (4w)
- 1
- 11
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Cognizant Technology Solutions Corporation
Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. The company operates through four segments: Financial Services; Healthcare; Products and Resources; and Communications, Media and Technology. It offers customer experience enhancement, robotic process automation, analytics, and AI services in areas, such as digital lending, fraud detection, and next generation payments; and enhanced compliance, integrated health management, claims investigative services, and patient experience, as well as services that drive operational improvements in areas, such as claims processing, enrollment, membership, and billing to healthcare providers and payers, and life sciences companies, including pharmaceutical, biotech, and medical device companies. The company also provides solution to manufacturers, retailers and travel and hospitality companies, as well as companies providing logistics, energy and utility services; and cloud, interactive, and IoT services to information, media and entertainment, and communications and technology companies. Cognizant Technology Solutions Corporation was founded in 1994 and is headquartered in Teaneck, New Jersey.
Latest CERS
- Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
- Chief Legal Officer Jensen Chrystal sold $89,529 worth of shares (30,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 936,657 units (SEC Form 4)
- SEC Form S-8 filed by Cerus Corporation
- SEC Form 10-Q filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cerus Corporation Announces Second Quarter 2026 Financial Results
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
Latest CTSH
- 80% of Employees Want to Use AI More Than Their Jobs Allow
- SEC Form 8-K filed by Cognizant Technology Solutions Corporation
- Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences
- Belcan Receives Pratt & Whitney Premier Awards for Overall Excellence in Business Management and Technology & Innovation
- Cognizant Selected by SITA to Deliver AI-Led Global Finance Transformation on the Cloud
- SEC Form 4 filed by Cognizant Technology Solutions Corporation
- Cognizant Launches Cognizant Activate to Bring Enterprise AI Transformation for Emerging Enterprises
- SVP, Controller & CAO Kerdman Alina sold $7,906 worth of shares (139 units at $56.88) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 1,124 units (SEC Form 4)
- Cognizant Schedules Third Quarter 2026 Earnings Release and Conference Call
- Cognizant Named to Forbes World's Best Employers 2026 List